220 related articles for article (PubMed ID: 28445541)
1. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
2. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
[TBL] [Abstract][Full Text] [Related]
3. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
Shelly S; Chien MB; Yip B; Kent MS; Theon AP; McCallan JL; London CA
Mamm Genome; 2005 Mar; 16(3):211-7. PubMed ID: 15834638
[TBL] [Abstract][Full Text] [Related]
4. RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
Crowe MS; Zavorotinskaya T; Voliva CF; Shirley MD; Wang Y; Ruddy DA; Rakiec DP; Engelman JA; Stuart DD; Freeman AK
Mol Cancer Res; 2021 Jun; 19(6):1063-1075. PubMed ID: 33707308
[TBL] [Abstract][Full Text] [Related]
5. Quercetin suppresses the proliferation of multiple myeloma cells by down-regulating IQ motif-containing GTPase activating protein 1 expression and extracellular signal-regulated kinase activation.
Ma Y; Jin Z; Huang J; Zhou S; Ye H; Jiang S; Yu K
Leuk Lymphoma; 2014 Nov; 55(11):2597-604. PubMed ID: 24397597
[TBL] [Abstract][Full Text] [Related]
6. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
7. Hierarchical scaffolding of an ERK1/2 activation pathway.
Vetterkind S; Poythress RH; Lin QQ; Morgan KG
Cell Commun Signal; 2013 Aug; 11():65. PubMed ID: 23987506
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
9. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
12. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
13. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
[TBL] [Abstract][Full Text] [Related]
14. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
[TBL] [Abstract][Full Text] [Related]
15. IQGAP1 regulates ERK1/2 and AKT signalling in the heart and sustains functional remodelling upon pressure overload.
Sbroggiò M; Carnevale D; Bertero A; Cifelli G; De Blasio E; Mascio G; Hirsch E; Bahou WF; Turco E; Silengo L; Brancaccio M; Lembo G; Tarone G
Cardiovasc Res; 2011 Aug; 91(3):456-64. PubMed ID: 21493702
[TBL] [Abstract][Full Text] [Related]
16. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
17. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
18. IQGAP1 modulates activation of B-Raf.
Ren JG; Li Z; Sacks DB
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10465-9. PubMed ID: 17563371
[TBL] [Abstract][Full Text] [Related]
19. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
[TBL] [Abstract][Full Text] [Related]
20. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
